SFS
NGM

Sowell Financial Services’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Sowell Financial Services’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-384
Closed -$12K – 3350
2020
Q4 		$12K Buy
384
+268
+231% +$5.86K ﹤0.01% 1957
2020
Q3 		$2K Buy
+116
New +$2.12K ﹤0.01% 2294
2020
Q2 		– Sell
-1,884
Closed -$24K – 2713
2020
Q1 		$24K Sell
1,884
-1,408
-43% -$23K ﹤0.01% 1335
2019
Q4 		$61K Buy
+3,292
New +$48.1K ﹤0.01% 1088

Other funds holding NGM

CG
Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
GA
Greenspring Associates Owings Mills, Maryland $1.48B AUM 61.93% 1-Year Est. Return
EC
Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return
PIM
Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return
PM
Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return

Sowell Financial Services's NGM Position: Q1 2021 in Review

Sowell Financial Services sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q1 2021, closing a stake of 384 shares — an estimated $12K sold.

Sowell Financial Services first reported a position in NGM in Q4 2019 and held it in 4 quarters. The position peaked at $61K in Q4 2019. 108 funds tracked by Wall St. Rank hold NGM as of Q1 2021.

  • Sowell Financial Services reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Sowell Financial Services sold 384 NGM Biopharmaceuticals, Inc. Common Stock shares in Q1 2021, an estimated $12K.
  • Sowell Financial Services first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q4 2019 and held it in 4 quarters.
  • Sowell Financial Services's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $61K in Q4 2019.
  • 108 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q1 2021.

Based on Sowell Financial Services's 13F filing for Q1 2021, filed 7 May 2021.